The prognostic impact of age, gender, ethnicity, melanoma subtype, M category (extent of distant metastasis), BRAF mutational status, cKIT mutational status, PD1 inhibitor therapy and the use of non-PD1 inhibitor systemic therapies on overall survival was analysed. Here, BRAF is linked to melanoma.